Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Description of Business, Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)

Description of Business, Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)				1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 15, 2024 USD ($)	Jun. 01, 2017 USD ($)	Feb. 01, 2012 USD ($)	Dec. 31, 2005 USD ($)	Aug. 31, 2024 USD ($) shares	Aug. 31, 2023 USD ($)	Aug. 31, 2024 USD ($) Unit Segment shares	Aug. 31, 2023 USD ($)
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Number of reportable segments \| Segment							3
Deferred revenue					$ 55,025,049		$ 55,025,049
Warranty payment		$ 100,000	$ 75,000	$ 50,000
Commission paid					9,813	$ 10,061	35,306	$ 31,451
Additional capitalized contract acquisition costs, net of amortization expense					28,876	30,185	90,545	85,133
Impairment of contract assets					0		0
Uncertain tax provisions					0		0
Provisions for interest or penalties related to uncertain tax positions							0	0
Impairment on long lived assets					0	0	0	0
Stock-based option compensation expense					145,941	172,099	631,435	641,690
Unrealized holding (losses) gains, marketable securities					522,458	93,386	1,056,052	100,082
Payment warranty				$ 50,000
Increased payment warranty		$ 100,000	$ 75,000
Gain (loss) on interest rate swap	$ 228,000				0	282,731	105,887	58,757
Other Nonoperating Income (Expense) [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Unrealized holding (losses) gains, marketable securities					$ 522,458	$ 93,386	$ 1,056,052	$ 100,082
Celle Corp [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Number of shares issued \| shares					0		0
Duke University [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Contracted storage amortization period					16 years		16 years
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] \| Duke University [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Agreement expiration date							Jan. 31, 2025
Inventory, in units \| Unit							6,000
Number of units, per month \| Unit							36
Maximum [Member] \| Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] \| Duke University [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Inventory, in units \| Unit							36
Accounts Receivables [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Period of doubtful for accounts receivable due from client							30 days
Option One [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Contracted storage amortization period					1 year		1 year
Option Two [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Contracted storage amortization period					21 years		21 years
Option Three [Member]
Business, Basis of Presentation and Significant Accounting Policies [Line Items]
Contracted storage amortization period							life-time
Contracted storage amortization description							The life-time storage plan is based on a life expectancy of 81 years, which is the current estimate by the Center for Disease Control for United States women’s life expectancy and concluded that additional data analysis would result in an immaterial difference in revenue.